Sight Sciences is an eyecare technology company developing interventional treatments for prevalent eye diseases. Founded in 2010 by brothers Paul and David Badawi and headquartered in Menlo Park, California, it reports two segments: Interventional Glaucoma, anchored by the implant-free OMNI and OMNI Edge Surgical Systems for minimally invasive canaloplasty and trabeculotomy in primary open-angle glaucoma, plus the SION device; and Interventional Dry Eye, anchored by TearCare, a wearable thermal therapy for meibomian gland dysfunction. The company listed on Nasdaq in July 2021 as SGHT and reported 2025 revenue of $77.4 million.
Sight Sciences is publicly traded
IPO'd on Jul 15, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under SGHT.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2010
Employees
51–200
Total Funding
$118.63M
6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $118.63M across 6 rounds
Last updated 10-01-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Nov 2020 | Series F | $23.25M | — | D1 Capital Partners |
| Mar 18, 2020 | Series E | $30.15M | — | D1 Capital Partners |
| Aug 2019 | Series D | $30.75M | — | KCK Ltd. |
Paul Badawi
Co-Founder & Chief Executive Officer
David Badawi
Co-Founder
Alison (Ali) Bauerlein
Chief Operating Officer
James (Jim) Rodberg
Chief Financial Officer
Jeremy Hayden
General Counsel
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Glaukos
Public ophthalmic medical device company and the dominant player in MIGS, marketing the iStent family of trabecular micro-bypass stents for glaucoma; the most direct competitor to Sight Sciences' OMNI Surgical System.
Alcon
Global eye-care company that strengthened its MIGS position by acquiring Ivantis (maker of the Hydrus Microstent) for $475M, competing directly with Sight Sciences in surgical glaucoma.
Johnson & Johnson Vision
Ophthalmic division of J&J that markets the SION surgical instrument and other glaucoma devices, competing in the MIGS and broader surgical ophthalmology space.
Nova Eye Medical
Australian ophthalmic device company offering the iTrack microcatheter for canaloplasty, a direct competitor to OMNI in MIGS canaloplasty.
Bausch + Lomb
Global eye-health company with a portfolio of dry-eye treatments (e.g., Miebo) competing with Sight Sciences' TearCare System in the dry eye disease market.
iSTAR Medical
Belgian ophthalmic device company developing the MINIject supraciliary glaucoma implant, an emerging MIGS competitor.
Yes, Sight Sciences is publicly traded under the ticker symbol SGHT on the NASDAQ. The company went public in Jul 15, 2021.
Sight Sciences trades under the ticker symbol SGHT on the NASDAQ. It began trading in Jul 15, 2021.
Sight Sciences (SGHT on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker SGHT to place an order.
Sight Sciences went public in Jul 15, 2021 via ipo. Sight Sciences completed its initial public offering on the Nasdaq Global Market on July 15, 2021, pricing 11.5 million shares at $24.00 per share for gross proceeds of $276 million and an implied valuation of approximately $1 billion. The company trades under the ticker SGHT.
Sight Sciences raised $118.63M across 6 disclosed funding rounds prior to its public listing.
Sight Sciences was co-founded by Paul Badawi, and David Badawi in 2010.
Sight Sciences is headquartered in Menlo Park, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.